In fact, FDA approved drugs targeting the MAPK pathway are currently available.35 It also remains feasible, however, that the PD-1/PD-L1 axis may enhance pancreatic cancer growth by unexplored signaling pathways. This evidence concerns the gene CD274 and pancreatic neoplasm.